Predatory bacteria: a potential ally against multidrug-resistant Gram-negative pathogens

PloS One
Daniel E KadouriYohei Doi

Abstract

Multidrug-resistant (MDR) Gram-negative bacteria have emerged as a serious threat to human and animal health. Bdellovibrio spp. and Micavibrio spp. are Gram-negative bacteria that prey on other Gram-negative bacteria. In this study, the ability of Bdellovibrio bacteriovorus and Micavibrio aeruginosavorus to prey on MDR Gram-negative clinical strains was examined. Although the potential use of predatory bacteria to attack MDR pathogens has been suggested, the data supporting these claims is lacking. By conducting predation experiments we have established that predatory bacteria have the capacity to attack clinical strains of a variety of ß-lactamase-producing, MDR Gram-negative bacteria. Our observations indicate that predatory bacteria maintained their ability to prey on MDR bacteria regardless of their antimicrobial resistance, hence, might be used as therapeutic agents where other antimicrobial drugs fail.

References

Jul 21, 2004·Nature Reviews. Microbiology·R Elizabeth Sockett, Carey Lambert
Jul 8, 2005·Applied and Environmental Microbiology·Daniel E Kadouri, George A O'Toole
Feb 2, 2006·Current Microbiology·Amy M RogoskyElizabeth A B Emmert
Nov 14, 2006·Applied and Environmental Microbiology·Daniel E KadouriGeorge A O'Toole
Dec 19, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James H Jorgensen, Janet F Hindler
Mar 16, 2007·Public Health Reports·R Monina KlevensDenise M Cardo
Jul 7, 2009·Annual Review of Microbiology·R Elizabeth Sockett
Sep 21, 2010·International Journal of Hygiene and Environmental Health·Natalia Y Markelova
Oct 12, 2010·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Alexander J Kallen, Arjun Srinivasan
Dec 1, 2010·Journal of Applied Microbiology·Aliza DashiffDaniel E Kadouri
Mar 16, 2011·Antimicrobial Agents and Chemotherapy·Guo-Bao TianYohei Doi
Mar 1, 2012·BMB Reports·Mohammed DwidarRobert J Mitchell
Apr 12, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Young Ah KimYohei Doi

Citations

May 9, 2014·Future Microbiology·Robert M Q Shanks, Daniel E Kadouri
Jan 1, 2015·Microorganisms·Riccardo RussoNancy D Connell
Jun 24, 2014·Annals of the New York Academy of Sciences·Heather K AllenThomas A Casey
Mar 29, 2014·Environmental Microbiology·Mohammed DwidarRobert J Mitchell
Dec 15, 2015·Environmental Microbiology·Juana PérezJosé Muñoz-Dorado
Aug 9, 2016·BMC Medicine·Sze-Ann Woon, Dale Fisher
Aug 17, 2016·Scientific Reports·Eric G RomanowskiRobert M Q Shanks
Feb 9, 2017·Canadian Journal of Microbiology·Damian McNeelySusan F Koval
May 10, 2017·Future Microbiology·Kenneth ShatzkesDaniel E Kadouri
Jan 14, 2017·Trends in Microbiology·J Tyson, R Elizabeth Sockett
Mar 7, 2017·Scientific Reports·Kenneth ShatzkesDaniel E Kadouri
Dec 30, 2015·Applied and Environmental Microbiology·Somdatta MukherjeeDaniel E Kadouri
Nov 12, 2016·MBio·Kenneth ShatzkesDaniel E Kadouri
Nov 22, 2015·Applied and Environmental Microbiology·Gary P RichardsMichael A Watson
Sep 1, 2016·PloS One·Shilpi GuptaDaniel E Kadouri
Mar 21, 2019·The Journal of Infectious Diseases·Vincent Cattoir, Brice Felden
Jun 13, 2019·FEMS Microbiology Letters·Alan R Pacheco, Daniel Segrè
Aug 5, 2017·Microbial Biotechnology·Wing Fei Wong, Marina Santiago
Oct 9, 2019·Advanced Pharmaceutical Bulletin·Fataneh Hashempour-BaltorkMatin Alizadeh
Jun 15, 2016·MicrobiologyOpen·Omotayo Opemipo OyedaraMario Alberto Rodriguez-Perez
May 14, 2017·Scientific Reports·Kenneth ShatzkesNancy D Connell
Jun 15, 2017·Médecine sciences : M/S·Edouard Jurkevitch, Stéphan Jacquet
May 10, 2017·BMC Microbiology·Casey BepplerPamela J Yeh
Mar 2, 2016·Environmental Microbiology Reports·Ryan M ChanyiJoanna S Brooke
Feb 16, 2019·Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine·Hayk Minasyan
Jan 24, 2017·EFSA Journal·EMA Committee for Medicinal Products for Veterinary Use (CVMP) and EFSA Panel on Biological Hazards (BIOHAZ)Helen Jukes
Sep 29, 2020·Frontiers in Bioengineering and Biotechnology·Wen Kang ChouMark P Brynildsen
May 12, 2019·Scientific Reports·James S FindlayPetra C F Oyston
Mar 17, 2020·Applied Microbiology and Biotechnology·Robert J MitchellSeong Yeol Choi
Jun 3, 2020·Microbial Biotechnology·Zulema Udaondo, María José Huertas
Aug 12, 2017·Scientific Reports·Tommi Mononen, Lasse Ruokolainen
May 29, 2019·Environmental Microbiology·Rajesh SathyamoorthyEdouard Jurkevitch
Mar 29, 2018·Disease Models & Mechanisms·Gina M Duggan, Serge Mostowy
Jul 25, 2018·Frontiers in Pharmacology·Randolph Stone IiRobert J Christy
Oct 18, 2020·Antibiotics·Shashi B KumarOuliana Ziouzenkova
Oct 10, 2020·Computational and Structural Biotechnology Journal·Juana PérezJosé Muñoz-Dorado
Jan 20, 2021·Microbiology·Robert J Atterbury, Jess Tyson
Feb 13, 2021·Frontiers in Microbiology·Manoj KumarRajnarayan R Tiwari

Methods Mentioned

BETA
PCR
culture collection

Related Concepts

Interference, Bacterial
Bdellovibrio
Alkalescens-Dispar Group
Klebsiella rhinoscleromatis
Pseudomonas
Alphaproteobacteria
Drug Resistance, Multiple, Bacterial
Acinetobacter baumannii
Virus Viability
Disk Diffusion Antimicrobial Tests

Related Feeds

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.